Company Overview

Alpha Teknova, Inc. is a U.S.-based life sciences company that manufactures and supplies critical reagents used in the research, development, and commercialization of advanced therapies, diagnostics, and bioprocessing applications. The company operates primarily within the biotechnology and pharmaceutical supply chain, providing products that support cell and gene therapy, molecular diagnostics, vaccine development, and research-use laboratory workflows. Its core offerings include custom and catalog solutions such as buffers, media, resins, and synthetic nucleic acids designed to meet regulatory and quality requirements.

The company’s primary revenue drivers are the manufacture and sale of synthetic DNA and RNA, critical process buffers, and other specialty reagents sold to biotechnology companies, pharmaceutical manufacturers, diagnostic developers, and academic or government research institutions. Alpha Teknova is positioned as a high-quality, scalable supplier with expertise in regulatory-compliant manufacturing, including products suitable for clinical and commercial-stage use. Founded in 1996, the company evolved from a custom reagent provider into a publicly traded life sciences supplier, completing its initial public offering in 2021 and expanding its focus on advanced therapy and diagnostic markets.

Business Operations

Alpha Teknova operates as a single integrated business focused on the development, manufacture, and commercialization of life sciences reagents, with operations centered on its Life Sciences Reagents business. Revenue is generated through a combination of catalog product sales and custom manufacturing agreements, with customers ranging from early-stage research organizations to commercial-scale biopharmaceutical manufacturers. The company emphasizes long-term supply relationships, particularly where customers require consistent quality and regulatory documentation across clinical development stages.

Operations are primarily domestic, with manufacturing, quality control, and distribution based in the United States, while serving a global customer base. Alpha Teknova controls proprietary manufacturing processes, quality systems aligned with current Good Manufacturing Practices (cGMP), and formulation expertise for complex reagents. Public disclosures indicate no material joint ventures; the company operates largely through its wholly owned corporate structure. Data on material subsidiaries beyond the core operating entity is inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Alpha Teknova focuses on growth aligned with the expansion of cell and gene therapies, mRNA-based technologies, and molecular diagnostics. The company has invested in capacity expansion, process automation, and quality infrastructure to support customers transitioning from research-scale to clinical and commercial production. Its strategy emphasizes becoming a preferred long-term supplier for critical reagents embedded in regulated therapeutic and diagnostic workflows.

The company has historically favored organic investment over large-scale acquisitions, directing capital toward facility expansion, equipment, and technical capabilities rather than acquiring other businesses. Alpha Teknova is actively involved in emerging sectors such as gene editing, viral vector production, and mRNA therapeutics through the products it supplies, rather than through equity investments or ownership of downstream technologies. No material acquisitions or portfolio company ownership have been confirmed in public filings.

Geographic Footprint

Alpha Teknova is headquartered in North America, with its principal facilities and corporate headquarters located in California, United States. The company’s manufacturing and operational footprint is concentrated domestically, which supports regulatory compliance and supply reliability for U.S.-based and international customers.

Despite its U.S.-centric operations, Alpha Teknova maintains a global commercial reach, supplying customers across North America, Europe, and parts of Asia-Pacific through direct sales and distribution channels. International exposure is primarily revenue-based rather than asset-based, with no publicly disclosed foreign manufacturing facilities as of the most recent reporting periods.

Leadership & Governance

Alpha Teknova is led by an executive team with experience across life sciences manufacturing, biopharmaceutical operations, and regulated supply chains. The leadership team emphasizes operational excellence, quality-driven growth, and alignment with long-term customer development timelines in regulated markets.

Key executives include:

• Stephen Gunstream – President and Chief Executive Officer
• Brian Gaffney – Chief Financial Officer
• E. Scott Murphy – Chief Operating Officer
• Mark Delaney – Chief Commercial Officer

The company operates under a public-company governance framework, with oversight from an independent board of directors. Leadership philosophy, as reflected in public disclosures, centers on disciplined capital allocation, customer integration, and scaling infrastructure to support advanced therapies and diagnostics. Data regarding founders’ ongoing involvement is inconclusive based on available public sources.